Pharma BD Deal Intelligence
Novartis AG / Molecular Partners AG
2020 · Licensing/Option · $780M · Complete
Announcement Sentiment
88
Strongly positive
Outcome Score
48
Mixed — partial payoff, real shortfalls.
Novartis licensed Molecular Partners' MP0310, a bispecific DARPin targeting FAP and 4-1BB for immuno-oncology combinations.
Key facts
- Announced Jan 10, 2020
- Deal value $780M
- Deal type Licensing/Option
- Therapeutic area Infectious Disease, Oncology
- Indications Solid tumors
- Key assets MP0310
- Mechanism FAP/4-1BB bispecific DARPin
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals